Author(s):
Prashant Kumar Sahu, Jitendra Yadav, Dolly Dewangan, Kamraj, Krity Gupta, Manish Kumar Sahu, Parimal Verma, Shweta Sinha, Aakanksha Sinha, S. J. Daharwal
Email(s):
Email ID Not Available
DOI:
10.52711/2321-581X.2025.00016 
Address:
Prashant Kumar Sahu*, Jitendra Yadav, Dolly Dewangan, Kamraj, Krity Gupta, Manish Kumar Sahu, Parimal Verma, Shweta Sinha, Aakanksha Sinha, S. J. Daharwal
University Institute of Pharmacy, Pt. Ravishankar Shukla University, Raipur (C.G).
*Corresponding Author
Published In:
Volume - 16,
Issue - 4,
Year - 2025
ABSTRACT:
Desvenlafaxine, the primary active compound found in venlafaxine, is used to treat major depressive disorder in adults as a serotonin-norepinephrine reuptake inhibitor. Its pharmacological effects come from selectively inhibiting SERT and NET, with a stronger preference for serotonin transporters. Studies have shown that desvenlafaxine has a moderate but reliable effectiveness as an antidepressant, although not as powerful as venlafaxine. Recent findings suggest that it could also be beneficial for managing pain, supported by changes seen in VAS-PI scores. Various methods, such as UV spectrophotometry, HPTLC, HPLC, UHPLC, and LC-MS/MS, have been developed to measure desvenlafaxine in raw material, formulations, and biological samples. These methods differ in how sensitive and specific they are, as well as their practical use, but there has not been a comprehensive review of their performance. This article summarizes the pharmacological actions, clinical effects, and all known analytical techniques for desvenlafaxine to serve as a comprehensive resource for research and quality control purposes.
Cite this article:
Prashant Kumar Sahu, Jitendra Yadav, Dolly Dewangan, Kamraj, Krity Gupta, Manish Kumar Sahu, Parimal Verma, Shweta Sinha, Aakanksha Sinha, S. J. Daharwal. A Review on pharmacology and recent analytical methods for estimation of Desvenlafaxine hydrochloride. Research Journal of Engineering and Technology. 2025; 16(4):162-6. doi: 10.52711/2321-581X.2025.00016
Cite(Electronic):
Prashant Kumar Sahu, Jitendra Yadav, Dolly Dewangan, Kamraj, Krity Gupta, Manish Kumar Sahu, Parimal Verma, Shweta Sinha, Aakanksha Sinha, S. J. Daharwal. A Review on pharmacology and recent analytical methods for estimation of Desvenlafaxine hydrochloride. Research Journal of Engineering and Technology. 2025; 16(4):162-6. doi: 10.52711/2321-581X.2025.00016 Available on: https://rjetonline.com/AbstractView.aspx?PID=2025-16-4-4
REFERENCE:
1. Norman TR, Olver JS. Desvenlafaxine in the treatment of major depression: an updated overview. Expert Opin Pharmacother. 2021 June 13;22(9):1087–97.
2. Perry R, Cassagnol M. Desvenlafaxine: A new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder. Clin Ther. 2009 Jan;31:1374–404.
3. Naseeruddin R, Rosani A, Marwaha R. Desvenlafaxine. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Nov 2]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK534829/
4. Pawar SM, Dhaneshwar SR. Application Of Stability Indicating High Performance Thin Layer Chromatographic Method For Quantitation Of Desvenlafaxine In Pharmaceutical Dosage Form. J Liq Chromatogr Relat Technol. 2012 Feb 15;35(4):499–510.
5. Lieberman DZ. Desvenlafaxine in major depressive disorder: an evidence-based review of its place in therapy. Core Evid. 2009 June;67.
6. Shelton RC. Serotonin Norepinephrine Reuptake Inhibitors: Similarities and Differences. Prim Psychiatry. 2009;16(5).
7. Kornstein SG, McIntyre RS, Thase ME, Boucher M. Desvenlafaxine for the treatment of major depressive disorder. Expert Opin Pharmacother. 2014 July 3;15(10):1449–63.
8. Andrade C. Desvenlafaxine. Indian J Psychiatry. 2009;51(4):320–3.
9. Nichols AI, Tourian KA, Tse SY, Paul J. Desvenlafaxine for major depressive disorder: incremental clinical benefits from a second-generation serotonin–norepinephrine reuptake inhibitor. Expert Opin Drug Metab Toxicol. 2010 Dec;6(12):1565–74.
10. Munoli RN, Praharaj SK, Bhandary RP, Selvaraj AG. Desvenlafaxine-induced worsening of hypertension. J Neuropsychiatry Clin Neurosci. 2013;25(2):E29-30.
11. DeMaio W, Kane C, Nichols A, Jordan R. Metabolism Studies of Desvenlafaxine. J Bioequivalence Bioavailab. 2011 Jan 1;03.
12. Carlsson AM. Assessment of chronic pain. I. Aspects of the reliability and validity of the visual analogue scale: Pain. 1983 May;16(1):87–101.
13. Kalyani L, Harpriya C, Rehana M. Analytical method development and validation for Desvenlafaxine Succinate by UV-Visible Spectroscopy Method. Int J Pharm. 2022;
14. Patil MG, Banerjee SK, Bonde CG, Chhabra gs. Uv spectrophotometric method development for the determination of desvenlafaxine succinate in tablet formulation.
15. Manjusha N. Dole*, Amit S. Minase, Sangeeta Chowdhary and Sanjay D. Sawant. Development and validation of analytical methods for estimation of desvenlafaxine succinate in bulk and solid dosage forms by UV spectroscopy. Sch Res Libr. 2013;
16. Shah D, Nakrani R, Baldania S, Chhalotiya U, Bhatt K. Development and validation of HPTLC method for the estimation of desvenlafaxine in tablet formulation. J Planar Chromatogr – Mod TLC. 2012 Apr;25(2):174–7.
17. Tawale H, Tajne M. Validated High Performance Thin Layer Chromatography Method For Determination Of Desvenlafaxine Succinate In Tablet.
18. Pawar SM, Khatal LD, Gabhe SY, Dhaneshwar SR. LC–UV and LC–MS evaluation of stress degradation behavior of desvenlafaxine. J Pharm Anal. 2012 Aug;2(4):264–71.
19. Shah D, Nakrani R, Baldania S, Chhalotiya U, Bhatt K. Stability indicating liquid chromatographic method for the estimation of desvenlafaxine in pharmaceutical dosage form. Chem Ind Chem Eng Q. 2011;17(3):341–8.
20. Kancharla PK, Kondru VGR, Dannana GS. Novel LC‐ ESI‐MS/MS method for desvenlafaxine estimation human plasma: application to pharmacokinetic study. Biomed Chromatogr. 2016 Feb;30(2):249–55.
21. Moussa BA, El-Bagary RI, Al-Eryani YA. Development and Validation of a Stability-Indicating HPLC Method for the Analysis of Desvenlafaxine Succinate in the Presence of its Acidic Induced Degradation Product in Bulk and Pharmaceutical Preparation. 2011;
22. Rao H, Ahmad S, Madni A, Ahmad I, Shahzad MN. Single-step extraction for simultaneous quantification of desvenlafaxine and alprazolam in human spiked plasma by RP-HPLC. Sailor G, editor. PLOS ONE. 2020 Sept 17;15(9):e0238954.
23. Akter H, Alam MM, Rabbi MR, Shamsur Rouf AS. Stability-Indicating UHPLC Method for the Determination of Desvenlafaxine: Application to Degradation Kinetics. Dhaka Univ J Pharm Sci. 2021 Dec 29;20(2):167–76.
24. Dziurkowska E, Wesolowski M. Simultaneous quantitation of venlafaxine and its main metabolite, O-desmethylvenlafaxine, in human saliva by HPLC. J Sep Sci. 2013;36(11):1726–33.
25. Vankadari RMG, P P, G.V R, Y G. Development and validation of stability indicating rp-hplc method for the determination of desvenlafaxine in extended release tablets. Indo Am J Pharm Res. 2013 Jan 1;3:7325–35.